Title : Synchronous Duodenal Cancer and Lung Cancer Harboring an Epidermal Growth Factor Receptor Mutation Treated with Erlotinib and Oral Fluoropyrimidine.

Pub. Date : 2017 Sep 1

PMID : 28794362






3 Functional Relationships(s)
Download
Sentence
Compound Name
Protein Name
Organism
1 Synchronous Duodenal Cancer and Lung Cancer Harboring an Epidermal Growth Factor Receptor Mutation Treated with Erlotinib and Oral Fluoropyrimidine. 2-fluoropyrimidine epidermal growth factor receptor Homo sapiens
2 We describe a case of synchronous duodenal cancer with lung cancer harboring an epidermal growth factor receptor (EGFR) mutation treated with erlotinib and S-1, an oral fluoropyrimidine agent. 2-fluoropyrimidine epidermal growth factor receptor Homo sapiens
3 We describe a case of synchronous duodenal cancer with lung cancer harboring an epidermal growth factor receptor (EGFR) mutation treated with erlotinib and S-1, an oral fluoropyrimidine agent. 2-fluoropyrimidine epidermal growth factor receptor Homo sapiens